EyePoint, Inc. Files Lawsuit Against Ocular Therapeutix for Alleged False and Misleading Statements

Key Highlights:

• Company Involved: EyePoint, Inc. (NASDAQ: EYPT)
• Date of Event: March 20, 2026
• Nature of Event: EyePoint, Inc. has filed a complaint against Ocular Therapeutix, Inc. in the Middlesex County Superior Court, Commonwealth of Massachusetts.
• Allegations: The complaint alleges, among other things, that Ocular Therapeutix has engaged in:
  • Unfair or deceptive acts or practices in violation of Massachusetts General Laws Chapter 93A, Sections 2 and 11
  • Tortious interference with advantageous business relations
  • Dissemination of false and misleading representations of fact
• Relief Sought: EyePoint is seeking:
  • Injunctive relief to prevent Ocular Therapeutix from further disseminating the alleged false or misleading statements
  • A public retraction of the false and misleading statements by Ocular Therapeutix
  • Monetary damages
  • Attorneys’ fees and costs
  • Any other relief the court deems just and proper

Details and Potential Shareholder Impact

The legal action initiated by EyePoint, Inc. is a significant development for shareholders, as lawsuits of this nature can have material impacts on both companies involved. The allegations of unfair competition and dissemination of false information, if proven, could not only impact Ocular Therapeutix’s reputation but may also enhance EyePoint’s competitive standing in the marketplace.

The lawsuit’s request for injunctive relief and public retraction targets the immediate halting of any potentially damaging statements, which may help protect EyePoint’s business relationships and market perception. Should EyePoint prevail and win monetary damages or attorneys’ fees, this could result in a direct financial benefit to the company. Additionally, a court-ordered public retraction from Ocular Therapeutix could be viewed favorably by investors, potentially restoring or strengthening EyePoint’s reputation.

It is important for investors to monitor developments in this case, as legal proceedings can influence company valuations, particularly if the outcome materially affects competitive advantages, ongoing business operations, or financial results. While the outcome of the litigation cannot be predicted at this stage, the company’s proactive stance in defending its interests may signal management’s commitment to protecting shareholder value.

Other Important Corporate Information

• EyePoint, Inc. is not an emerging growth company, as indicated in their filing.
• The company’s common stock trades on the Nasdaq Global Market under the symbol EYPT.
• There were no written communications, soliciting materials, or tender offers associated with this filing.
• The filing was signed by George O. Elston, Executive Vice President and Chief Financial Officer, on March 20, 2026.

Disclaimer

Disclaimer: This article is for informational purposes only and does not constitute legal or investment advice. The actual outcome of legal proceedings is uncertain and could materially differ from the expectations set forth above. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions related to EyePoint, Inc., Ocular Therapeutix, Inc., or their securities.

View EyePoint, Inc. Historical chart here